We administered reduced L-hOmoCySteineperorally (67 moWkg of body wt) to 12 healthy subjects and injected the same dose into one person, and determined the kinetics of the alterations in reduced, oxidized, and protein-bound concentrations of homocysteine, cysteine, and cysteinyiglycine. After oral intake, reduced homocysteine increased rapidly 15 mm), reaching concentrations [3.97 (SD 2.99) mol/L] 20-fold above fasting values, and then declined towards the normal concentration within 2 h. There was a similar increase in reduced cysteine and a moderate increase in reduced cysteinylglycine. During this response, we observed a positive correlation between the reduced/total ratio for homocysteine and cysteine. When homocysteine was injected, the increase in reduced homocysteine preceded the increase in reduced cysteine by about 3 mm. After oral loading, Despite the growing evidence that plasma homocysteine is a cardiovascular risk factor, the mechanism behind the vascular injuries stifi remains coijectural. Mechanistic studies are hampered by the fact that little is known about which homocysteine species prevail(s) in vivo. In freshly prepared plasma from healthy subjects, the major fraction is protein bound and most free homecysteine exists as homocysteine-cysteine mixed disulfide (6). We recently developed a procedure for determining reduced, oxidized, and protein-bound homocysteine and other thiol components in human plasma. The procedure is based on trapping thiols by collecting blood directly into evacuated tubes containing thiol-reactive agents (7). Using this method, we detected significant amounts of reduced homocysteine in plasma from healthy subjects (7). The reduced fraction was markedly increased after an oral intake of methionine (8). Perhaps more important, in eight patients with homocystinuria, reduced homocysteine was increased to 200 times the amount in healthy subjects (9). In both healthy subjects and patients, increased amounts of reduced homocysteine in plasma were associated with increased concentrations of reduced cysteine and cysteinyiglycine and decreased protein-binding of these thiol components (8, 9).
homocystinuria caused by various genetic defects is associated with early vascular disease suggests that homocysteine is responsible for the vascular lesions (3). This hypothesis has motivated investigations to determine whether a moderate increase of plasma homocysteine (hyperhomocysteinemia) is a risk factor for cardiovascular disease. Studies performed up to now, including about 1800 patients and a comparable number of controls, have shown a significant relation between hyperhomocysteinemia and premature cardiovascular disease (4, 5).
Despite the growing evidence that plasma homocysteine is a cardiovascular risk factor, the mechanism behind the vascular injuries stifi remains coijectural. Mechanistic studies are hampered by the fact that little is known about which homocysteine species prevail(s) in vivo. In freshly prepared plasma from healthy subjects, the major fraction is protein bound and most free homecysteine exists as homocysteine-cysteine mixed disul-
fide (6).
We recently developed a procedure for determining reduced, oxidized, and protein-bound homocysteine and other thiol components in human plasma. The procedure is based on trapping thiols by collecting blood directly into evacuated tubes containing thiol-reactive agents (7) . Using this method, we detected significant amounts of reduced homocysteine in plasma from healthy subjects (7) . The reduced fraction was markedly increased after an oral intake of methionine (8). Perhaps more important, in eight patients with homocystinuria, reduced homocysteine was increased to 200 times the amount in healthy subjects (9). In both healthy subjects and patients, increased amounts of reduced homocysteine in plasma were associated with increased concentrations of reduced cysteine and cysteinyiglycine and decreased protein-binding of these thiol components (8, 9).
The presence of large amounts of reduced homocysteine in homocystinuric patients and small amounts in healthy subjects complies with the idea that this species plays a role in atherogenesis. Moreover, the increased amount of reduced homocysteine may have marked effects on the redox status of other thiols, as demonstrated for cysteine and cysteinyiglycine, and these remote chemical effects may disturb normal cellular function. Notably, there is recent evidence that reduced homocysteine and cysteine may play a role in atherogenesis by supporting cell-mediated generation of reactive oxygen species that modify low-density lipoproteins to a form that is taken up by macrophages via the scavenger receptor (10, 11).
In the present work we investigated the effect of the increase in reduced, oxidized, and protein-bound homocysteine after homocysteine administration on the redox status of other thiol components in plasma. The magnitude and kinetics of this response together with a low plasma methionine concentration simplify the interpretation of the results. The data we obtained support the idea that homocysteine has an immediate and direct effect on the redox status and protein binding of other aminothiols in human plasma.
MaterIals and Methods

Materials and Subjects
Sources of most reagents were as given previously (7 Thiols in blood collected into a tube with mBrB react with this reagent and form fluorescent adducts. The blood cells are removed by centrifugation, and the plasma proteins by acid precipitation.
Chromatographic analysis of the acid-soluble supernate yields the free, reduced forms of homocysteine, cysteine, and cysteinylglycune.
When blood is collected into a solution containing NEM, the reduced sulthyckyl groups are rapidly trapped as their NEM adducts. The plasma fraction is then deproteinized with acid, and the disulfides are reduced in the presence of NaBH4 to their corresponding thiols, which are then derivatized with mBrB. With this procedure we determined the oxidized, free forms of homecysteine, cysteine, and cysteinylglycine.
Total amounts of homocysteine, cysteine, and cysteinylglycune in plasma were determined by reducing the disulfides in whole plasma with NaBH4 and derivatizing the free thiols with mBrB.
The protein-bound fraction was calculated by subtracting the quantities of the reduced and the oxidized species from the total amount.
The thiol-mBrB adducts are separated by ion-paired liquid chromatography on an ODS-Hypersil colunm. Further details on these assays have been published previously (7).
Statistics.
Variation in a particular analyte during the 48 h after the homocysteine loading was analyzed by the Friedman test (nonparametric analysis of variance) and by repeated-measures analysis of variance. The latter test was also used to evaluate the sex-related differences.
In cases where significant (P <0.05) changes were obtained, the values before loading and the maximal response after loading were compared by using the Wilcoxon matched-pair signed rank test. The relationship between the reduced/total ratio for various plasma thiols was assessedby using linear correlation. P values are given for a test for zero correlation; all P values are given as two-tailed, and values <0.025 are considered significant.
Results
Homocysteine loading.
Six healthy men and six healthy women were included in this study. Their fasting plasma concentrations of different forms of homocysteine, cysteine, and cysteinyiglycine are listed in Table  1 . The values for total homocysteine, cysteinylglycine, and cysteine were within the normal ranges (6, 13). After the subjects were given a standard oral dose of freshly prepared reduced homocysteine, the plasma concentrations of reduced, oxidized, and protein-bound thiol componentsin men were not significantly different from those in women. In the rest of our presentation, the data from men and women are treated as a single population.
Reduced homocysteine and other thiol components.
There was a rapid (t,,,, <15 miii), significant (P <0.005) increase in reduced homocysteune in plasma from 0.04 (SD 0.026) to 3.97 (SD 2.99) imoIfL after the oral homocysteine loading. Then the concentration rapidly normalized, corresponding to a rate of -0.9 h' ( Figure  1, upper panel) .
Reduced cysteine showed similar kinetics (t = 15 mm), but the increase (P <0.005) relative to the fasting concentration was less pronounced, from 4.68 (SD 1.93) to 8.64 (SD 3.93) moI/L (Figure 1, middle panel) . There was a concurrent moderate but significant (P <0.05) increase [from 1.66 (SD 0.49) to 2.4 (SD 0.61) moJJL] in reduced cysteinylglycune (Figure 1, lower panel) .
We also investigated in the individual subjects the relation between the reduced/total ratios (the fraction of the total amount that exists in the reduced form) for the plasma thiol components homocysteine intake ( Figure 2 ). There was a significant correlation by linear-regression analysis between the reduced/total ratio for homocysteine and cysteine; the relation vs the ratio for cysteinylglycine was weaker. However, the reduced/total ratios for cysteine and cysteinylglycine were closely related, especially after 30 mm (Figure 2) .
The initial kinetics of the increase of the reduced species could be distinguished in the plasma from the subject who was injected with homocysteine. Reduced homocysteine peaked after <1 mmiiand preceded the increase in reduced cysteine and cysteinylglycine, Time after homocysteine loading (hours) Oxidized homocysteine increased significantly (P <0.005 at 30 miii) for a brief time after the oral homocysteine loading but the response (t,, =30 miii) lagged behind the increase in the reduced form, and the decline towards the preload values proceeded more slowly. The amounts of oxidized cysteine and cysteinylglycine were not significantly altered (Figure 4) .
Protein binding. Protein-bound homocysteine showed the slowest response after loading (t,,, = 1-2 h, P <0.005) and gradually (at a rate of about 0.15 h') approached the preload value. Protein-bound cysteine decreased (t = 1 h, P <0.005), and the decrease mirrored the increase in protein-bound homocysteine. A moderate decrease was also observed for protein-bound cysteinylglycine.
Notably, the decrease in proteinbound cysteine plus cysteinylglycune was somewhat greater than the corresponding increase of proteinbound homocysteine (Figure 5) .
DIscussion
We have previously demonstrated that small amounts of reduced homocysteine exist in plasma from healthy subjects (7, 8) , and this thiol increases significantly during the transient hyperhomocysteinemia induced by methionine loading. There is a concurrent complex effect on the protein binding of other thiol components such as cysteine and cysteinylglycune in plasma (8) .
The homocysteine response after methionune loading is preceded by the enzymic formation of S-adenosylmethionine, followed by the formation of S-adenosylhomocysteine, which is finally hydrolyzed to homocysteine (1) . Accordingly, the homocysteine response is a slow process, reaching a maximum in 2-6 h (8), which therefore does not allow evaluation of the kinetics of interaction between homocysteine and other thiol components in vivo. Furthermore, the amount of reduced homocysteune is only slightly increased (8), which makes estimates on the relation between thiols in plasma difficult. Finally, high plasma concentrations of methionune may add a confounding factor because this may enhance the production of cysteine and probably cysteinylglycine in the liver (14) . Conceivably, administered homocysteine may also serve as a cysteine precursor, but this metabolic conversion must be preceded by distribution of homocysteine into liver and other tissues, and is probably a late event relative to the peak plasma homocysteine concentration.
We observed that freshly prepared reduced homocysteine in solution is rapidly absorbed, causes a transient increase in the various forms of homocysteine, and affects other thiol components in human plasma (Figures 1-5) . This experimental design allows the conclusion that the homocysteine increase is the primary event and the alterations in other thiol components are secondary phenomena. In addition, the increase in reduced homocysteine was sufficiently high to allow assessment of kinetics and the relation to other plasma thiol components.
The transient increase in reduced homocysteine is closely followed by an increase in reduced cysteine, and the kinetics of these twop are similar. There is a concurrent small increase in reduced cysteinylglycune (Figure 1 ). This suggests that reduced homocysteine undergoes a disulfide interchange reaction with cysteine-mixed and symmetric disulfides. The observation that a positive correlation exists between the reduced/ total ratios for homocysteine and cysteine and cysteinylglycine, and for cysteine vs cysteinyiglycine (Figure 2) , suggests that there is an equilibrium state between these species, and that such an equilibrium is reached within 15 mm in vivo.
The time course for the increase of the reduced forms after intravenous administration shows that homocysteine was greatest immediately after infusion (55 s), whereas both cysteine and cysteinylglycune lagged behind and peaked after about 4 mm (Figure 3) . This observation also demonstrates that the increase of homocysteine is the primary event and suggests that the time required to reach equilibrium is about 3 minalthough this time may be underestimated because of the progressive decrease in homocysteine.
The finding discussedabove shows that the reduction potential of homocysteine is sufficiently high to reduce other biological thiol componentsat physiological pH, as demonstrated in the present work for cysteine and cysteinylglycine, and previously in subjects receiving a methionine loading (8) and in homocystinurics (9).
Conceivably, alteration of the redox status of other biological thiol components in addition to cysteine and cysteinyiglycine during hyperhomocysteinemia may occur, and should be considered potentially
